Alimera Sciences Company Profile (NASDAQ:ALIM)

About Alimera Sciences (NASDAQ:ALIM)

Alimera Sciences logoAlimera Sciences, Inc. (Alimera) is a pharmaceutical company. The Company is engaged in the research, development and commercialization of prescription ophthalmic pharmaceuticals. The Company operates through two segments: U.S. and International. The Company focuses on diseases affecting the back of the eye or retina. The Company's product is ILUVIEN, which is developed to treat diabetic macular edema (DME). DME is a disease of the retina that affects individuals with diabetes and can lead to severe vision loss and blindness. In the United States, ILUVIEN is indicated for the treatment of DME in patients who have been treated with a course of corticosteroids and did not have a rise in intraocular pressure (IOP). In the European Economic Area (EEA) countries, ILUVIEN is indicated for the treatment of vision impairment associated with DME considered insufficiently responsive to available therapies.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Biopharmaceuticals
  • Sub-Industry: N/A
  • Symbol: NASDAQ:ALIM
  • CUSIP: N/A
  • Web: www.alimerasciences.com
Capitalization:
  • Market Cap: $99.43 million
  • Outstanding Shares: 69,050,000
Average Prices:
  • 50 Day Moving Avg: $1.47
  • 200 Day Moving Avg: $1.41
  • 52 Week Range: $1.03 - $1.72
P/E:
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -48.00
  • P/E Growth: 0.00
Sales & Book Value:
  • Annual Revenue: $35.96 million
  • Price / Sales: 2.77
  • Book Value: ($0.70) per share
  • Price / Book: -2.06
Profitability:
  • EBIDTA: ($16,780,000.00)
  • Net Margins: -68.58%
  • Return on Assets: -36.39%
Debt:
  • Debt-to-Equity Ratio: -0.72%
  • Current Ratio: 4.63%
  • Quick Ratio: 4.51%
Misc:
  • Average Volume: 307,850 shs.
  • Beta: 2.16
  • Short Ratio: 1.77
 

Frequently Asked Questions for Alimera Sciences (NASDAQ:ALIM)

What is Alimera Sciences' stock symbol?

Alimera Sciences trades on the NASDAQ under the ticker symbol "ALIM."

How were Alimera Sciences' earnings last quarter?

Alimera Sciences, Inc. (NASDAQ:ALIM) posted its quarterly earnings data on Wednesday, August, 2nd. The company reported ($0.04) earnings per share for the quarter, beating the Zacks' consensus estimate of ($0.05) by $0.01. The company had revenue of $10.40 million for the quarter, compared to analysts' expectations of $10.20 million. The firm's quarterly revenue was up 8.3% on a year-over-year basis. During the same period in the previous year, the firm earned ($0.17) earnings per share. View Alimera Sciences' Earnings History.

When will Alimera Sciences make its next earnings announcement?

Alimera Sciences is scheduled to release their next quarterly earnings announcement on Tuesday, October, 31st 2017. View Earnings Estimates for Alimera Sciences.

Where is Alimera Sciences' stock going? Where will Alimera Sciences' stock price be in 2017?

3 brokers have issued 12 month price objectives for Alimera Sciences' shares. Their predictions range from $3.00 to $5.00. On average, they expect Alimera Sciences' share price to reach $4.00 in the next year. View Analyst Ratings for Alimera Sciences.

What are analysts saying about Alimera Sciences stock?

Here are some recent quotes from research analysts about Alimera Sciences stock:

  • 1. According to Zacks Investment Research, "Alimera Sciences, Inc., based in Alpharetta, Georgia, is a biopharmaceutical company that specializes in the research, development and commercialization of prescription ophthalmic pharmaceuticals. The Company is presently focused on diseases affecting the back of the eye, or retina because it believes these diseases are not well treated with current therapies and represent a significant market opportunity. Its product candidate Iluvien(R) is an intravitreal insert containing fluocinolone acetonide, a non-proprietary corticosteroid with demonstrated efficacy in the treatment of ocular disease. Iluvien is in development for the treatment of diabetic macular edema (DME). DME is a disease of the retina that affects individuals with diabetes and can lead to severe vision loss and blindness. " (8/17/2017)
  • 2. Cowen and Company analysts commented, "Positive Iluvien results were published in the journal Eye" for the treatment of DME." (7/25/2017)

Who are some of Alimera Sciences' key competitors?

Who are Alimera Sciences' key executives?

Alimera Sciences' management team includes the folowing people:

  • Richard S. Eiswirth Jr., President, Chief Financial Officer
  • Rich Cockrell, President
  • C. Daniel Myers, Chief Executive Officer
  • Kenneth E. Green Ph.D., Senior Vice President, Chief Scientific Officer
  • David R. Holland, Senior Vice President - Sales and Marketing
  • Philip Ashman, Senior Vice President, European Managing Director
  • Mark J. Brooks, Independent Director
  • Brian K. Halak Ph.D., Independent Director
  • Peter J. Pizzo III, Independent Director

Who owns Alimera Sciences stock?

Alimera Sciences' stock is owned by a variety of of institutional and retail investors. Top institutional shareholders include Palo Alto Investors LLC (4.60%), Vanguard Group Inc. (2.47%), JW Asset Management LLC (1.49%), Goldman Sachs Group Inc. (0.46%), Parkwood LLC (0.35%) and Stonepine Capital Management LLC (0.28%). Company insiders that own Alimera Sciences stock include C Daniel Myers, Calvin W Roberts, James E Flynn, Kenneth Green, LP Bavp, Richard S Eiswirth Jr and Richard S Eiswirth, Jr. View Institutional Ownership Trends for Alimera Sciences.

Who sold Alimera Sciences stock? Who is selling Alimera Sciences stock?

Alimera Sciences' stock was sold by a variety of institutional investors in the last quarter, including Stonepine Capital Management LLC, Vanguard Group Inc. and Goldman Sachs Group Inc.. Company insiders that have sold Alimera Sciences stock in the last year include C Daniel Myers and Richard S Eiswirth Jr. View Insider Buying and Selling for Alimera Sciences.

Who bought Alimera Sciences stock? Who is buying Alimera Sciences stock?

Alimera Sciences' stock was bought by a variety of institutional investors in the last quarter, including JW Asset Management LLC and PNC Financial Services Group Inc.. Company insiders that have bought Alimera Sciences stock in the last two years include Calvin W Roberts and James E Flynn. View Insider Buying and Selling for Alimera Sciences.

How do I buy Alimera Sciences stock?

Shares of Alimera Sciences can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Alimera Sciences' stock price today?

One share of Alimera Sciences stock can currently be purchased for approximately $1.44.


MarketBeat Community Rating for Alimera Sciences (NASDAQ ALIM)
Community Ranking:  2.5 out of 5 (  )
Outperform Votes:  96 (Vote Outperform)
Underperform Votes:  98 (Vote Underperform)
Total Votes:  194
MarketBeat's community ratings are surveys of what our community members think about Alimera Sciences and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Consensus Ratings for Alimera Sciences (NASDAQ:ALIM) (How are Consensus Ratings Calculated?)
Ratings Breakdown: 3 Buy Ratings
Consensus Rating:Buy (Score: 3.00)
Consensus Price Target: $4.00 (177.78% upside)

Analysts' Ratings History for Alimera Sciences (NASDAQ:ALIM)
Show:
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
8/3/2017Cowen and CompanySet Price TargetBuy$3.00LowView Rating Details
8/4/2017HC WainwrightSet Price TargetBuy$5.00HighView Rating Details
4/27/2017Rodman & RenshawInitiated CoverageBuy -> Buy$4.00HighView Rating Details
3/4/2016Cantor FitzgeraldLower Price TargetBuy$6.00 -> $5.00N/AView Rating Details
11/26/2015Credit Suisse GroupLower Price Target$5.00 -> $4.00N/AView Rating Details
(Data available from 8/20/2015 forward)

Earnings

Earnings History for Alimera Sciences (NASDAQ:ALIM)
Earnings by Quarter for Alimera Sciences (NASDAQ:ALIM)
Earnings History by Quarter for Alimera Sciences (NASDAQ ALIM)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
10/31/2017($0.05)N/AView Earnings Details
8/2/2017Q2 2017($0.05)($0.04)$10.20 million$10.40 millionViewListenView Earnings Details
5/8/2017Q1 2017($0.08)($0.10)$8.80 million$6.62 millionViewListenView Earnings Details
3/1/2017Q4 2016($0.07)($0.10)$10.60 million$10.70 millionViewListenView Earnings Details
11/2/2016Q316($0.11)($0.16)$10.53 million$8.30 millionViewN/AView Earnings Details
8/3/2016Q2($0.19)($0.17)$8.42 million$3.80 millionViewN/AView Earnings Details
5/4/2016Q1($0.19)($0.22)$5.83 million$5.80 millionViewN/AView Earnings Details
11/5/2015Q315($0.22)($0.21)$6.96 million$6.90 millionViewN/AView Earnings Details
8/10/2015Q215($0.22)($0.25)$6.49 million$5.80 millionViewListenView Earnings Details
5/7/2015Q115($0.24)($0.27)$3.90 million$3.90 millionViewN/AView Earnings Details
3/4/2015Q414($0.16)($0.28)$5.11 million$1.70 millionViewN/AView Earnings Details
11/6/2014Q314($0.70)($0.22)$3.75 million$2.40 millionViewN/AView Earnings Details
8/7/2014Q214($0.23)($0.15)$2.70 million$2.19 millionViewN/AView Earnings Details
5/8/2014Q114($0.25)($0.20)$1.15 million$2.08 millionViewN/AView Earnings Details
2/27/2014Q413($0.29)($0.24)$0.75 million$0.94 millionViewN/AView Earnings Details
11/11/2013Q313($0.30)($0.26)$0.38 million$0.76 millionViewN/AView Earnings Details
8/12/2013Q2 2013($0.24)($0.30)$3.00 millionViewN/AView Earnings Details
5/9/2013Q1 2013($0.26)($0.27)ViewN/AView Earnings Details
3/21/2013Q4 2012($0.23)($0.17)ViewN/AView Earnings Details
11/7/2012Q312($0.19)($0.17)ViewN/AView Earnings Details
3/8/2012($0.24)($0.19)ViewN/AView Earnings Details
11/3/2011($0.19)($0.21)ViewN/AView Earnings Details
8/4/2011($0.18)($0.17)ViewN/AView Earnings Details
5/5/2011($0.20)($0.15)ViewN/AView Earnings Details
2/10/2011($0.22)($0.20)ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Alimera Sciences (NASDAQ:ALIM)
Current Year EPS Consensus Estimate: $-0.22 EPS
Next Year EPS Consensus Estimate: $-0.03 EPS

Dividends

Dividend History for Alimera Sciences (NASDAQ:ALIM)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading and Institutional Ownership History for Alimera Sciences (NASDAQ:ALIM)
Insider Ownership Percentage: 14.00%
Institutional Ownership Percentage: 43.77%
Insider Trades by Quarter for Alimera Sciences (NASDAQ:ALIM)
Institutional Ownership by Quarter for Alimera Sciences (NASDAQ:ALIM)
Insider Trades by Quarter for Alimera Sciences (NASDAQ:ALIM)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
3/10/2017C. Daniel MyersCEOSell21,172$1.39$29,429.08View SEC Filing  
9/15/2016Richard S Eiswirth JrInsiderSell51,471$1.51$77,721.21View SEC Filing  
4/21/2016L.P. BavpMajor ShareholderSell478,673$2.59$1,239,763.07View SEC Filing  
12/16/2015Richard S. Eiswirth, Jr.CFOSell46,669$2.31$107,805.39View SEC Filing  
12/8/2015James E FlynnInsiderBuy272,249$3.01$819,469.49View SEC Filing  
12/3/2015James E FlynnInsiderBuy243,252$3.00$729,756.00View SEC Filing  
10/30/2015James E FlynnInsiderBuy16,542$3.00$49,626.00View SEC Filing  
10/28/2015James E FlynnInsiderBuy59,342$3.00$178,026.00View SEC Filing  
10/26/2015James E FlynnInsiderBuy60,364$3.00$181,092.00View SEC Filing  
10/21/2015James E FlynnMajor ShareholderBuy160,684$3.00$482,052.00View SEC Filing  
10/20/2015James E FlynnMajor ShareholderBuy100,130$3.00$300,390.00View SEC Filing  
10/19/2015James E FlynnMajor ShareholderBuy129,226$2.92$377,339.92View SEC Filing  
10/15/2015Richard S. Eiswirth, Jr.CFOSell13,625$2.69$36,651.25View SEC Filing  
10/9/2015James E FlynnInsiderBuy321,785$2.42$778,719.70View SEC Filing  
9/3/2015Calvin W RobertsDirectorBuy6,424$3.00$19,272.00View SEC Filing  
8/21/2015Kenneth GreenSVPSell20,000$3.29$65,800.00View SEC Filing  
8/17/2015Kenneth GreenSVPSell20,000$3.90$78,000.00View SEC Filing  
6/26/2015L.P. BavpMajor ShareholderSell1,024$5.00$5,120.00View SEC Filing  
6/19/2015L.P. BavpMajor ShareholderSell5,568$5.00$27,840.00View SEC Filing  
5/1/2015C. Daniel MyersCEOSell2,000$4.37$8,740.00View SEC Filing  
4/27/2015L.P. BavpMajor ShareholderSell3,114$5.02$15,632.28View SEC Filing  
4/23/2015L.P. BavpMajor ShareholderSell4,362$5.00$21,810.00View SEC Filing  
4/20/2015L.P. BavpMajor ShareholderSell30,300$5.03$152,409.00View SEC Filing  
4/15/2015L.P. BavpMajor ShareholderSell35,800$5.03$180,074.00View SEC Filing  
4/14/2015L.P. BavpMajor ShareholderSell18,400$5.01$92,184.00View SEC Filing  
4/13/2015L.P. BavpMajor ShareholderSell100$5.00$500.00View SEC Filing  
3/6/2015Richard S Eiswirth JrCFOBuy10,000$4.84$48,400.00View SEC Filing  
3/2/2015C. Daniel MyersCEOSell2,000$5.21$10,420.00View SEC Filing  
1/2/2015C. Daniel MyersCEOSell2,000$5.51$11,020.00View SEC Filing  
1/2/2015David HollandSVPSell5,000$5.56$27,800.00View SEC Filing  
12/1/2014C. Daniel MyersCEOSell2,000$5.99$11,980.00View SEC Filing  
12/1/2014David HollandSVPSell5,000$5.71$28,550.00View SEC Filing  
10/27/2014L.P. BavpMajor ShareholderSell57,918$6.34$367,200.12View SEC Filing  
10/1/2014C. Daniel MyersCEOSell2,000$5.42$10,840.00View SEC Filing  
10/1/2014David HollandSVPSell5,000$5.26$26,300.00View SEC Filing  
10/1/2014Patrick LeeMajor ShareholderSell621,191$5.42$3,366,855.22View SEC Filing  
9/30/2014Patrick LeeMajor ShareholderSell354,062$5.42$1,919,016.04View SEC Filing  
9/29/2014Patrick LeeMajor ShareholderSell240,662$5.47$1,316,421.14View SEC Filing  
9/11/2014L.P. BavpMajor ShareholderSell2,816$6.25$17,600.00View SEC Filing  
9/4/2014L.P. BavpMajor ShareholderSell39,500$6.33$250,035.00View SEC Filing  
8/29/2014L.P. BavpMajor ShareholderSell7,400$6.27$46,398.00View SEC Filing  
8/28/2014L.P. BavpMajor ShareholderSell3,000$6.27$18,810.00View SEC Filing  
8/1/2014David HollandSVPSell5,000$5.64$28,200.00View SEC Filing  
7/1/2014David HollandSVPSell5,000$6.02$30,100.00View SEC Filing  
5/1/2014David HollandSVPSell5,000$5.93$29,650.00View SEC Filing  
3/4/2014C. Daniel MyersCEOSell22,775$7.10$161,702.50View SEC Filing  
3/4/2014David HollandSVPSell10,000$6.84$68,400.00View SEC Filing  
3/4/2014Susan CaballaInsiderSell8,931$7.01$62,606.31View SEC Filing  
1/16/2014Domain Partners Vi, L.P.Major ShareholderSell296,760$6.39$1,896,296.40View SEC Filing  
7/17/2013Polaris Venture Management CoInsiderSell122,937$4.80$590,097.60View SEC Filing  
6/20/2013Domain Partners Vi, L.P.Major ShareholderSell10,516$5.01$52,685.16View SEC Filing  
6/19/2013Domain Partners Vi, L.P.Major ShareholderSell55,278$5.39$297,948.42View SEC Filing  
6/18/2013Polaris Venture Management CoInsiderSell37,063$5.44$201,622.72View SEC Filing  
6/17/2013Domain Partners Vi, L.P.Major ShareholderSell126,709$5.29$670,290.61View SEC Filing  
6/11/2013Domain Partners Vi, L.P.Major ShareholderSell5,337$5.00$26,685.00View SEC Filing  
5/17/2013David HollandSVPSell30,000$4.13$123,900.00View SEC Filing  
5/16/2013Domain Partners Vi, L.P.Major ShareholderSell44,242$4.60$203,513.20View SEC Filing  
12/13/2012Peter J Pizzo IIIDirectorBuy5,000$1.44$7,200.00View SEC Filing  
12/3/2012C. Daniel MyersCEOSell7,700$1.95$15,015.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Headline Trends for Alimera Sciences (NASDAQ:ALIM)
Latest Headlines for Alimera Sciences (NASDAQ:ALIM)
Source:
DateHeadline
americanbankingnews.com logoAlimera Sciences, Inc. (ALIM) Downgraded by Zacks Investment Research
www.americanbankingnews.com - August 17 at 4:54 PM
nasdaq.com logoAlimera Sciences Announces Data to be Presented at the 2017 Annual ASRS Meeting - Nasdaq
www.nasdaq.com - August 9 at 8:58 PM
finance.yahoo.com logoAlimera Sciences Announces Data to be Presented at the 2017 Annual ASRS Meeting
finance.yahoo.com - August 9 at 3:56 PM
nasdaq.com logoAlimera Sciences' CEO Dan Myers to Present US Real-World ILUVIEN® Post-Marketing Data During Ophthalmology ... - Nasdaq
www.nasdaq.com - August 9 at 1:23 AM
globenewswire.com logoAlimera Sciences' CEO Dan Myers to Present US Real-World ILUVIEN® Post-Marketing Data During Ophthalmology ... - GlobeNewswire (press release)
globenewswire.com - August 8 at 2:43 AM
finance.yahoo.com logoAlimera Sciences' CEO Dan Myers to Present U.S. Real-World ILUVIEN® Post-Marketing Data During Ophthalmology Innovation Summit at ASRS, August 10, 2017
finance.yahoo.com - August 7 at 4:40 PM
americanbankingnews.com logoHC Wainwright Reiterates "$5.00" Price Target for Alimera Sciences, Inc. (NASDAQ:ALIM)
www.americanbankingnews.com - August 6 at 10:26 PM
seekingalpha.com logoAlimera Sciences' (ALIM) CEO Dan Myers on Q2 2017 Results ... - Seeking Alpha
seekingalpha.com - August 6 at 8:31 PM
americanbankingnews.com logoAlimera Sciences, Inc. (NASDAQ:ALIM) Given a $3.00 Price Target by Cowen and Company Analysts
www.americanbankingnews.com - August 6 at 6:28 PM
finance.yahoo.com logoEdited Transcript of ALIM earnings conference call or presentation 3-Aug-17 1:00pm GMT
finance.yahoo.com - August 5 at 3:32 PM
finance.yahoo.com logoAlimera Sciences reports 2Q loss
finance.yahoo.com - August 3 at 4:43 PM
americanbankingnews.com logoAlimera Sciences, Inc. (NASDAQ:ALIM) Releases Earnings Results, Beats Expectations By $0.01 EPS
www.americanbankingnews.com - August 3 at 3:39 PM
globenewswire.com logoAlimera Sciences Reports Second Quarter 2017 Financial Results - GlobeNewswire (press release)
globenewswire.com - August 3 at 1:41 AM
nasdaq.com logoAlimera Sciences Reports Second Quarter 2017 Financial Results
www.nasdaq.com - August 2 at 8:40 PM
americanbankingnews.com logoComparing Alimera Sciences (NASDAQ:ALIM) & Sinovac Biotech (SVA)
www.americanbankingnews.com - July 28 at 7:49 AM
reuters.com logoBRIEF-Alimera Sciences announces real-world audit data supporting positive benefits of iluvien treatment
www.reuters.com - July 26 at 1:34 AM
globenewswire.com logoAlimera Sciences Announces Real-World Audit Data Supporting the Positive Benefits of ILUVIEN® Treatment - GlobeNewswire (press release)
globenewswire.com - July 25 at 8:34 PM
finance.yahoo.com logoAlimera Sciences Announces Real-World Audit Data Supporting the Positive Benefits of ILUVIEN® Treatment
finance.yahoo.com - July 25 at 8:34 PM
americanbankingnews.com logoAlimera Sciences, Inc. (ALIM) to Release Quarterly Earnings on Tuesday
www.americanbankingnews.com - July 25 at 7:06 AM
finance.yahoo.com logoAlimera Sciences to Report Second Quarter 2017 Financial Results on August 2nd, 2017
finance.yahoo.com - July 24 at 1:26 PM
streetinsider.com logoAlimera Sciences (ALIM) Says MHRA Has Given Final Approval to Reduce Size of its ILUVIEN Registry Safety Study - StreetInsider.com
www.streetinsider.com - July 20 at 5:05 PM
nasdaq.com logoPositive Results Enable Alimera Sciences to Reduce Enrollment in ILUVIEN® Registry Safety Study in the UK - Nasdaq
www.nasdaq.com - July 19 at 4:54 PM
finance.yahoo.com logoPositive Results Enable Alimera Sciences to Reduce Enrollment in ILUVIEN® Registry Safety Study in the U.K.
finance.yahoo.com - July 19 at 4:54 PM
nasdaq.com logoLeading Retinal Specialists to Highlight pSivida's Durasert for Treatment of Posterior Segment Uveitis at ... - Nasdaq
www.nasdaq.com - July 18 at 5:10 PM
americanbankingnews.com logoZacks Investment Research Lowers Alimera Sciences, Inc. (NASDAQ:ALIM) to Hold
www.americanbankingnews.com - July 13 at 7:14 PM
finance.yahoo.com logoETFs with exposure to Alimera Sciences, Inc. : July 13, 2017
finance.yahoo.com - July 13 at 4:30 PM
nasdaq.com logoAlimera Sciences Announces Italian Patients Now Being Treated With ILUVIEN® - Nasdaq
www.nasdaq.com - July 12 at 4:09 PM
finance.yahoo.com logoAlimera Sciences Announces Italian Patients Now Being Treated With ILUVIEN®
finance.yahoo.com - July 12 at 4:09 PM
News IconBRIEF-Psivida out-licenses EMEA rights for Durasert three-year treatment for posterior segment Uveitis
www.businessinsider.com - July 11 at 5:00 PM
americanbankingnews.com logoCowen and Company Reaffirms "Buy" Rating for Alimera Sciences, Inc. (NASDAQ:ALIM)
www.americanbankingnews.com - July 11 at 4:10 PM
globenewswire.com logopSivida Out-licenses EMEA Rights for Durasert™ Three-year Treatment for Posterior Segment Uveitis While Retaining ... - GlobeNewswire (press release)
globenewswire.com - July 11 at 1:41 AM
globenewswire.com logoAlimera Sciences To Expand ILUVIEN® Indication in Europe for Posterior Uveitis - GlobeNewswire (press release)
globenewswire.com - July 10 at 8:41 PM
finance.yahoo.com logopSivida Out-licenses EMEA Rights for Durasert™ Three-year Treatment for Posterior Segment Uveitis While Retaining U.S. Commercial Rights; Amended Global Collaboration Agreement with Alimera for ILUVIEN® Improves pSivida’s Revenue Generation
finance.yahoo.com - July 10 at 8:41 PM
finance.yahoo.com logoAlimera Sciences To Expand ILUVIEN® Indication in Europe for Posterior Uveitis
finance.yahoo.com - July 10 at 8:41 PM
americanbankingnews.com logoAlimera Sciences, Inc. (ALIM) Upgraded by Zacks Investment Research to Buy
www.americanbankingnews.com - July 10 at 4:09 PM
finance.yahoo.com logoETFs with exposure to Alimera Sciences, Inc. : June 29, 2017
finance.yahoo.com - June 29 at 4:42 PM
finance.yahoo.com logoETFs with exposure to Alimera Sciences, Inc. : June 29, 2017
finance.yahoo.com - June 29 at 4:42 PM
finance.yahoo.com logoETFs with exposure to Alimera Sciences, Inc. : June 16, 2017
finance.yahoo.com - June 16 at 4:04 PM
finance.yahoo.com logoAlimera Sciences, Inc. :ALIM-US: Earnings Analysis: Q1, 2017 By the Numbers : June 14, 2017
finance.yahoo.com - June 14 at 3:28 PM
bizjournals.com logoResearch Reports Initiation on Drug Makers Stocks -- Immune Pharma, Impax Labs, Heron Therapeutics, and Alimera Sciences
www.bizjournals.com - June 2 at 4:33 PM
finance.yahoo.com logoBlog Coverage Eli Lilly's Late-Stage Bladder Cancer Drug CYRAMZA Meets Primary Endpoint
finance.yahoo.com - June 2 at 4:33 PM
seekingalpha.com logoAlimera Sciences' (ALIM) CEO Dan Myers on Q1 2017 Results ... - Seeking Alpha
seekingalpha.com - May 10 at 9:26 AM
globenewswire.com logoAlimera Sciences Reports First Quarter 2017 Financial Results ... - GlobeNewswire (press release)
globenewswire.com - May 10 at 9:26 AM
finance.yahoo.com logoEdited Transcript of ALIM earnings conference call or presentation 9-May-17 12:00pm GMT
finance.yahoo.com - May 9 at 8:28 PM
americanbankingnews.com logoAlimera Sciences Inc (ALIM) Issues Quarterly Earnings Results, Misses Estimates By $0.02 EPS
www.americanbankingnews.com - May 9 at 10:22 AM
finance.yahoo.com logoInvestor Network: ALIMERA SCIENCES INC to Host Earnings Call
finance.yahoo.com - May 9 at 9:21 AM
finance.yahoo.com logoAlimera Sciences Reports First Quarter 2017 Financial Results
finance.yahoo.com - May 8 at 8:26 PM
marketbeat.com logoAlimera Sciences reports 1Q loss
marketbeat.com - May 8 at 6:22 PM
americanbankingnews.com logoAlimera Sciences (ALIM) Receives Daily Media Impact Score of 0.24
www.americanbankingnews.com - May 4 at 3:54 PM
finance.yahoo.com logoAlimera Sciences to Report First Quarter 2017 Financial Results on May 8th, 2017
finance.yahoo.com - May 3 at 3:28 PM

Social

Chart

Alimera Sciences (ALIM) Chart for Sunday, August, 20, 2017

This page was last updated on 8/20/2017 by MarketBeat.com Staff